- Home
- MDGL
as of 12-12-2025 3:39pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 12.5B | IPO Year: | N/A |
| Target Price: | $553.08 | AVG Volume (30 days): | 313.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $265.00 - $605.00 | Next Earning Date: | 11-04-2025 |
| Revenue: | $740,640,000 | Revenue Growth: | 864.21% |
| Revenue Growth (this year): | 436.04% | Revenue Growth (next year): | 53.17% |
AI-Powered MDGL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
President and CEO
Avg Cost/Share
$575.34
Shares
2,400
Total Value
$1,380,816.00
Owned After
150,074
SEC Form 4
EVP and CFO
Avg Cost/Share
$581.45
Shares
4,173
Total Value
$2,413,416.41
Owned After
14,293
Director
Avg Cost/Share
$522.34
Shares
8,500
Total Value
$4,428,197.57
Owned After
27,152
Director
Avg Cost/Share
$485.61
Shares
16,575
Total Value
$8,027,354.15
Owned After
2,627
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sibold William John | MDGL | President and CEO | Dec 4, 2025 | Sell | $575.34 | 2,400 | $1,380,816.00 | 150,074 | |
| Dier Mardi | MDGL | EVP and CFO | Dec 2, 2025 | Sell | $581.45 | 4,173 | $2,413,416.41 | 14,293 | |
| Levy Richard S | MDGL | Director | Nov 13, 2025 | Sell | $522.34 | 8,500 | $4,428,197.57 | 27,152 | |
| BATE KENNETH | MDGL | Director | Nov 5, 2025 | Sell | $485.61 | 16,575 | $8,027,354.15 | 2,627 |
Compare MDGL vs Leading Stocks
See how MDGL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.